tbi-1201
Cell therapyexperimental
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2014 (NCT02096614)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Melanoma-associated antigen 4Immunity, passive
MAGEA4 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- tbi-1201
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02096614 | Phase 1 | Apr 1, 2014 | Fiverings Co., Ltd., Mie University, Shionogi, Statcom Co. Ltd., Takara Bio Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fiverings Co., Ltd. | For profit | 1 | 0 | 1 | 2014 |
| Mie University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Shionogi | For profit | 1 | 0 | 1 | 2014 |
| Statcom Co. Ltd. | For profit | 1 | 0 | 1 | 2014 |
| Takara Bio Inc. | For profit | 1 | 0 | 1 | 2014 |
5 organizations
Page 1 / 1